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Abstract
Toll-like receptors (TLRs) are important regulators of the innate immune response to pathogens, including Mycobacterium
leprae, which is recognized by TLR1/2 heterodimers. We previously identified a transmembrane domain polymorphism,
TLR1_T1805G, that encodes an isoleucine to serine substitution and is associated with impaired signaling. We hypothesized
that this TLR1 SNP regulates the innate immune response and susceptibility to leprosy. In HEK293 cells transfected with the
1805T or 1805G variant and stimulated with extracts of M. leprae, NF-kB activity was impaired in cells with the 1805G
polymorphism. We next stimulated PBMCs from individuals with different genotypes for this SNP and found that 1805GG
individuals had significantly reduced cytokine responses to both whole irradiated M. leprae and cell wall extracts. To
investigate whether TLR1 variation is associated with clinical presentations of leprosy or leprosy immune reactions, we
examined 933 Nepalese leprosy patients, including 238 with reversal reaction (RR), an immune reaction characterized by a
Th1 T cell cytokine response. We found that the 1805G allele was associated with protection from RR with an odds ratio (OR)
of 0.51 (95% CI 0.29–0.87, p=0.01). Individuals with 1805 genotypes GG or TG also had a reduced risk of RR in comparison to
genotype TT with an OR of 0.55 (95% CI 0.31–0.97, p=0.04). To our knowledge, this is the first association of TLR1 with a
Th1-mediated immune response. Our findings suggest that TLR1 deficiency influences adaptive immunity during leprosy
infection to affect clinical manifestations such as nerve damage and disability.
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Introduction
Mycobacterium tuberculosis (MTb) has established latent infection in
one-third of the world’s population and, among those with
progressive disease, causes about 2 million deaths per year [1].
Mycobacterium leprae (ML), a related organism, is the etiologic agent
of leprosy, an ancient scourge that still causes illness in several
regions of the world [2]. Both MTb and ML produce a spectrum
of illness in their hosts, yet, aside from frank immunodeficiency,
the host factors that underlie the various clinical manifestations of
MTb and ML infection are largely unknown. One possible
explanation for this diversity of outcomes is common, subclinical
variation in host defense genes.
Several lines of evidence suggest that genetic factors influence
susceptibility to leprosy and other Mycobacteria [1–5]. Rare
individuals with primary immunodeficiency syndromes are highly
susceptible to certain mycobacterial species due to Mendelian
disorders associated with highly penetrant phenotypes [2].
However, in most individuals, susceptibility to mycobacterial
infection is associated with complex inheritance patterns that are
determined by the combined effects of variation across many
genes, with a modest contribution from each polymorphism.
Evidence that commonly inherited gene variants influence
susceptibility to mycobacterial infection comes from twin studies,
genome-wide linkage studies, and candidate gene association
studies [2]. Studies of leprosy infection in twins have shown a
three-fold greater concordance for type of leprosy disease in
monozygotic compared to dizygotic twins [6]. Genome-wide
linkage studies have identified two single nucleotide polymor-
phisms (SNPs) in the shared promoter region of the PARK2 and
the PARCG gene, several HLA-DR2 alleles, and a non-HLA
region near chromosome 10p13 that are associated with leprosy or
leprosy subtypes [2,7,8]. Candidate gene association studies have
also shown associations between leprosy and polymorphisms in
several genes, including lymphotoxin-a (LTA) [9], the vitamin D
receptor [10], TNF-a [11], laminin-2 [12], and mannose binding
lectin [13,14].
Human infection with M. leprae presents a unique opportunity to
link innate and adaptive immune responses to host genetic factors.
Leprosy’s divergent clinical forms reflect two distinct immune
responses to the same pathogen. Lepromatous leprosy (defined as
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characterized by a Th2 immune response and poor containment
of the infection. At the opposite pole, tuberculoid leprosy (defined
as polar tuberculoid (TT) or borderline tuberculoid (BT)) features
a Th1 cytokine response, vigorous T cell responses to ML antigen,
and containment of the infection in well-formed granulomas
[15,16]. Reversal reactions (RR) represent the sudden activation of
a Th1 inflammatory response to ML antigens. They often occur
after the initiation of treatment in patients towards the
lepromatous pole of the leprosy spectrum (LL, BL, or borderline
borderline (BB) categories) and reflect a switch from a Th2-
predominant cytokine response toward a Th1-predominant
response [15,16]. Risk factors for RR intrinsic to the host include
age [17] and gene variants, although the latter have not been
intensively investigated [18,19].
Toll-like receptors (TLRs) are a family of highly conserved, type
1 transmembrane proteins that orchestrate the innate immune
response to microbial motifs, also known as pathogen associated
molecular patterns (PAMPs) [20–22]. The TLR pathway regulates
the innate immune response to mycobacteria through several
TLRs, including TLR1, 2, 4, 6, and 9 [23–26]. TLR2 (Online
Mendelian Inheritancce in Man (OMIM):603028), as a heterodi-
mer with TLR1 (OMIM: 601194) or TLR6 (OMIM: 605403),
mediates recognition of several mycobacterial motifs, including
lipopeptides, the 19 kDa protein, lipoarabinomannan (LAM)
[1,27,28]. Interaction of these ligands with the extracellular
domain of TLRs leads to activation of a signaling pathway, which
results in expression of chemokines and cytokines [20]. Functional
work by many investigators has shown that TLR2 is a critical
mediator of the innate immune response to ML and MTb [29,30].
In addition, several TLR2 polymorphisms have been reported to
be associated with susceptibility to MTb [31–33].
By contrast, very little is known about the effect of TLR1
variation on the innate response to mycobacteria or clinical
susceptibility to mycobacterial disease. It also remains controver-
sial whether and how the innate immune response mediated by
any individual TLR shapes adaptive immunity [34–37]. We
recently characterized a non synonymous SNP, T1805G (I602S),
in the transmembrane domain of TLR1 that regulates signaling in
response to PAM3, a synthetic ligand of TLR1 [38]. Johnson et al.
also found that this polymorphism was associated with decreased
signaling as well as protection from leprosy in Turkey [39].
Intriguingly, it appears that the TLR1 signaling defect is due to a
complete absence of TLR1 on the surface of monocytes in GG
individuals [39]. Here, we investigate an association of this SNP
with different clinical forms of leprosy in Nepal and examine the
effect of this SNP on leukocyte signaling in response to ML
stimulation.
Methods
Materials
RPMI Medium 1640, L-glutamine, penicillin-streptomycin, and
DMEM were from GIBCO/Invitrogen (Carlsbad, CA). Ultrapure
lipopolysaccharide (LPS) was from Salmonella minnesota R595 (List
Biological Labs, Inc.). Lipopeptides PAM2Cys-SKKKK (diacy-
lated, PAM2) and PAM3Cys-SKKK (triacylated, PAM3) were
from EMC Microcollections (Tuebingen, Germany). Macrophage-
activating Lipopeptide-2 S-[2,3-bis(Palmityloxy)-(2R)-propyl-cystei-
nyl-GNNDESNISFKEK] (diacylated lipopeptide from Mycoplasma
fermentens, Malp-2) was obtained from Alexis Biochemicals (Lausen,
Switzerland). M. leprae reagents were obtained from J. Spencer
(Colorado State University) through NIH, NIAID Contract No.
NO1-AI-25469, entitled ‘‘Leprosy Research Support.’’ HEK293
cells (ATCC#CRL-1573) were grown in DMEM (GIBCO cat.
no. #11995), supplemented with 10% fetal bovine serum, 10
units/ml penicillin, and 10 mg/ml streptomycin.
Human Subjects and Study Design
Study participants in Seattle were healthy adults with no known
history of unusual susceptibility to infections [40]. Study
participants in Nepal included 933 leprosy patients referred for
treatment at Anandaban Hospital in Katmandu, Nepal and later
recruited to a study of genetic factors influencing susceptibility to
reactional episodes in leprosy. The study population comprised
more than 8 different ethnic and religious groups that included
Brahmin (25.6%), Chhetri (22.3%), Tamang (14.3%), Newar
(7.3%), Magar (5.4%), Muslim (3.3%), Sarki (3.5%), and Kami
(2.7%), with 15.5% having unrecorded ethnicity A diagnosis of
leprosy and determination of leprosy type was made by clinical
symptoms, skin smears and biopsy reports. Assignment of leprosy
category followed the Ridley/Jopling classification scheme [41].
Each patient had a minimum of three years of regular clinic
follow-up prior to recruitment. In accord with guidelines of the US
Department of Health and Human Services, protocols were
approved by the Nepal Health Research Council, the University of
Washington, the University of Medicine and Dentistry of New
Jersey, and the Western Institutional Review Board. Written
informed consent was obtained from all patients or from their
relatives if the patient could not provide consent.
Molecular Biology
DNA from subjects in Nepal was obtained by extraction from
whole blood using Nucleon BACC2 Genomic DNA (Amersham
Lifesciences) and Roche High-Pure PCR template preparation
extraction kits. DNA from subjects in Seattle was extracted from
whole blood using QIAamp DNA Blood Midi kits (Qiagen,
Valenica, CA). Genotyping was carried out with a MassARRAY
technique (Sequenom) as previously described [42,43]. For
functional studies, the coding region of TLR1 was amplified from
genomic DNA and cloned into the pEF6/V5-His-TOPO vector
(Invitrogen, Carlsbad, CA) as previously described [38]. To obtain
Author Summary
Mycobacterium leprae (ML) causes a disabling and stigma-
tizing disease that is characterized by distinct immune
responses. ML produces a spectrum of illness in humans,
and several lines of evidence indicate that host genetic
factors influence susceptibility and clinical manifestations.
Leprosy can occur as the lepromatous or tuberculoid
forms, which are associated with different clinical mani-
festations, histopathology, T cell cytokine profiles, and
bacterial burden in affected sites. Leprosy is also associ-
ated with unique immunologic reactions, such as reversal
reaction, which is characterized by the rapid development
of a Th1 T cell cytokine response that can cause substantial
morbidity. We and others recently discovered a common
human polymorphism in TLR1 (T1805G, I602S) that
regulates cytokine production in response to lipopeptide
stimulation, influences the cellular innate immune re-
sponse to Mycobacteria, is associated with altered locali-
zation, and is present in 50% of individuals worldwide.
Here, we show that in humans the 1805G variant does not
mediate an inflammatory response to ML in vitro and that
this polymorphism is associated with protection from
reversal reaction. These data suggest that a common
variant of TLR1 is associated with altered adaptive immune
responses to ML as well as clinical outcome.
TLR1 and Leprosy Reversal Reaction
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with mutant primers was used as previously described [30].
Cytokine Assays
PBMCs were derived from whole blood separated by centrifu-
gation on a Ficoll-Hypaque gradient, plated at a density of 1610
5
cells per well in 96-well plates in RPMI (supplemented with 10%
fetal bovine serum), and incubated overnight. PBMC cytokine
assays were then performed by stimulating with various TLR
ligands or extracts of M. leprae for 18 hours. Each sample was
assayed in triplicate. Cytokine levels were determined with a
sandwich ELISA technique (Duoset, R&D Systems, Minneapolis,
MN) or with a multiplex kit for the luminex platform (Human
Fluorokine MAP Base Kit, Panel A, R&D systems, Minneapolis,
MN). Levels of contaminating LPS as determined by the
chromogenic Limulus amebocyte lysate test (Cambrex, MD) were
0.05–0.27, and 0.03–0.19 endotoxin units/ml, in wells incubated
with whole irradiated ML (ML) and ML cell wall (MLcw),
respectively, depending on the dose of reagent used. These values
correspond to 4.5–27.2 and 3.04–19.4 pg/ml of endotoxin,
respectively, in wells treated with whole irradiated ML and ML
cw. All wells that received ML reagents were additionally treated
with polymyxin B at a concentration of 10 mg/ml.
Transfections
HEK293 cells were transfected with Polyfect (Qiagen, Hilden,
Germany) per the manufacturer’s instructions with 2–5610
4 cells
per well in a 96-well plate with pRL-TK (to control for
transfection efficiency), ELAM-luciferase (NF-kB reporter), one
of two TLR1 variants, TLR2, and CD14. After an overnight
transfection, cells were stimulated with TLR ligands or extracts of
ML for 4–6 hours, and then lysed and processed for luciferase
readings per the manufacturer’s instructions for the Dual
Luciferase Reporter Assay System (Promega, Madison, WI).
Statistics
Univariate analysis was performed for categorical variables with
a Chi-Square test; Fisher’s exact test was used when the number of
samples in a group was less than 5. The Mann-Whitney U-test was
used to make comparisons of the cytokine production between
groups, as small sample sizes precluded an assumption of normal
distribution. Student’s t-test was used to compare results in the
luciferase assay. Two-sided testing was used for all comparisons to
evaluate statistical significance. A P value (p) of #0.05 was
considered significant. Statistics were calculated with Prism version
4.03software. For genetic analysis, allelic, genotypic, and haplo-
typic frequencies were compared between groups. Haplotypes
were constructed with an Expectation/Maximization (EM)
algorithm with the program HAPIPF in IC Stata (version 10.0)
[44]. Except for minor deviations, the observed allelic frequencies
of SNPs were consistent with expected frequencies under Hardy-
Weinberg equilibrium.
Results
TLR1 SNP T1805G regulates signalling in response to M.
leprae in transfected cells
We investigated the effect of SNP T1805G (I602S) on NF-kB
responses to ML in HEK293 cells transfected with 1805T (602I) or
1805G (602S), firefly luciferase conjugated to an NF-kB promoter
(ELAM), TLR2, CD14, and Renilla luciferase conjugated to
thymidine kinase to control for transfection efficiency [38]. Cells
were then stimulated with media, ML extracts or TLR ligands:
PAM3, a ligand for the TLR2/1 heterodimer or Malp-2, a ligand
for the TLR2/6 heterodimer (Fig 1). HEK293 cells transfected
with TLR2+1805T and stimulated with 50 mg/ml of whole,
irradiated ML had significantly greater NF-kB activity than
HEK293 cells transfected with TLR2 alone (600.7 vs. 159.8
relative luciferase units (RLU), p=0.001), or cells transfected with
TLR2+1805G (600.7 vs. 157.1 RLU, p=0.000004) (Fig 1).
Responses to ML were dose-dependent in cells transfected with
either TLR1 variant and the signaling difference between 1805T
and 1805G transfectants persisted over a range of doses
(comparison for ML 5 mg/ml: 511.9 vs. 75.8, p,0.0001;
comparison for ML 250 mg/ml: 673.7 vs. 262.8, p=0.0005). We
then investigated whether T1805G influenced signaling in
response to MLcw, which contains lipopeptide moieties known
to stimulate through TLR2/1 [29]. TLR2+1805T-transfected cells
stimulated with 1 or 10 mg/ml of MLcw had significantly greater
NF-kB activity than cells transfected with TLR2+1805G (Fig 1,
comparison for MLcw 1 mg/ml: 444.4 vs. 53.8 RLU, p=0.00005;
comparison for MLcw 10 mg/ml: 562.8 vs. 238.1 RLU,
p=0.004). As a control, we also compared baseline signalling
activity and response to tri-acylated lipopeptide (PAM3) in the two
1805 variants. Consistent with previous observations [38], the
1805T variant, when co-transfected with TLR2, mediated greater
constitutive NF-kB activity compared to TLR2 alone (Fig 1,
stimulation with media alone: 329.7 vs. 3.9 RLU, p=0.000003).
The TLR2+1805T transfectants were also readily distinguished
from the TLR2+1805G transfectants by a significantly higher level
of basal signaling (329.7 vs. 24.2 RLU, p=0.000002). In addition,
TLR2+1805T-transfected cells stimulated with PAM3 had
significantly greater NF-kB activity compared to cells transfected
with TLR2+1805G (841.4 vs. 383.7 RLU, p=0.0009). In
contrast, responses to Malp-2 did not significantly differ between
the two variants (783.1 vs. 650.6 RLU, p=0.37). Together, these
results suggest that TLR1 variant 1805G leads to impaired innate
immune responses to ML because of a defect in basal signaling of
the TLR2/1 heterodimer.
Figure 1. NF-kB activity in response to M. leprae is diminished in
the 1805T variant. HEK293 cells were transfected with an NF-kB
luciferase reporter, a Renilla luciferase construct to control for
transfection efficiency (pRL-TK), and CD14. Additional transfectants
varied by condition and included: empty plasmid vector (EV, clear), TLR2
alone (T2, gray), or TLR2 with one of two TLR1 constructs, 1805T (black)
or 1805G (stippled). Luciferase activity represents basal (media
stimulation) or stimulated activity of transfected cells. Mean values (+/
2standard deviation) are depicted for two representative experiments,
each performed in triplicate. RLU, relative luciferase units; P3 300, PAM3
at a dose of 300 ng/ml; M2 100, Malp-2, at 100 ng/ml; ML, whole,
irradiated ML at 5, 50, or 250 mg/ml; MLcw, M. leprae cell wall at a dose
of 1 or 10 mg/ml. *=P#0.01, by Student’s t-test when comparing the
1805T and 1805G variants (both with T2); #=P#0.01, by Student’s t-
test when comparing T2+1805T and T2;ˆ
=P#0.01, by Student’s t-test
when comparing T2+1805G and T2.
doi:10.1371/journal.pntd.0000231.g001
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to M. leprae in human monocytes
We next examined whether TLR1_T1805G regulates innate
immune responses to ML in human primary immune cells. We
obtained PBMC from whole blood from 28 healthy individuals
whose genotypes for TLR1_T1805G had previously been
determined [38]. The PBMCs were then stimulated with whole,
irradiated ML, MLcw, and a variety of TLR ligands, including
PAM3, PAM2, and LPS. We compared the high (1805TT) and
medium (1805TG) responding genotypes with the low responding
genotype (1805GG) (Fig 2). When stimulated with MLcw, PBMCs
from 1805TT or 1805TG (1805TT/TG) donors showed signif-
icantly greater IL-6 responses compared to 1805GG PBMCs
(Fig 2B, for MLcw at 2 mg/ml: 5,950 vs. 2,198 pg/ml, p=0.0005;
for MLcw at 10 mg/ml: 6,115 vs. 3,320 pg/ml, p=0.0076).
Similarly, responses to whole, irradiated ML were significantly
higher in 1805TT/TG PBMCs compared to 1805GG PBMCs
(Fig 2B, for whole, irradiated ML at 20 mg/ml: 3,310 vs.
1,649 pg/ml, p=0.0005; for whole, irradiated ML at 100 mg/
ml: 6,183 vs. 2,246 pg/ml, p=0.0017). As previously observed,
after stimulation with PAM3, significantly higher levels of IL-6
were seen in PBMCs heterozygous or homozygous for 1805T
compared to1805GG PBMCs (Fig 2A, for TT/TG genotypes vs.
GG genotypes stimulated with 75 mg/mL PAM3: 3,966 vs.
1,491 pg/ml, p=0.0007). Stimulation with LPS and PAM2,
ligands with specificity for TLR4 and TLR2/6, respectively,
produced no significant differences in IL-6 production between the
two groups (Fig 2A). We also assessed the levels of other cytokines
important in the monocyte immune response to mycobacteria and
found that IL-1b production in PBMCs from 1805TT/TG donors
stimulated with PAM3 or whole irradiated ML was significantly
higher than in 1805GG PBMCs (Fig 3A). IL-1b levels did not
differ between the two groups when PBMCs were stimulated with
PAM2 or with LPS (TLR2/6 and TLR4 ligands, respectively)
controls. Production of TNF-a, similarly, was significantly higher
in 1805TT/TG PBMCs stimulated with PAM3, whole irradiated
ML, or MLcw compared to 1805GG PBMCs (Fig 3B), but did not
differ between the two groups after stimulation with Pam2 or LPS
(TLR2/6 and TLR4 controls) (Fig 3B). Interestingly, there were
no differences in IL-1b levels between TT/TG and GG groups
after PBMC stimulation with MLcw, in contrast to the pattern
seen with other cytokines (Fig 2B, 3A).
TLR1 is not associated with altered risk of tuberculoid or
lepromatous forms of leprosy
Although recently published data suggests that TLR1_T1805G
is associated with susceptibility to leprosy, associations with
different types of leprosy or immunologic reactions have not been
previously examined. To determine whether the TLR1_T1805G
polymorphism was associated with different forms of leprosy or
leprosy immune reactions, 933 patients from Anandaban Hospital
in Kathmandu, Nepal were enrolled in a retrospective study. Of
this total, 581 had polar lepromatous (LL), borderline leprosy (BL)
or borderline borderline (BB) and 343 had tuberculoid leprosy
(including borderline tuberculoid (BT) and polar tuberculoid
(TT)). A total of 344 patients experienced immune reactions
during 3 years of regular visits to a leprosy clinic, of whom 238 had
RR and 108 had erythema nodosum leprosum (ENL) and 2 had
both reactions. The baseline characteristics of this population are
described in Table 1. When individuals with lepromatous leprosy
were compared to those with tuberculoid leprosy, there were no
significant associations between SNP T1805G and either form of
leprosy, either at the allelic or genotypic level of analysis (Table 2).
However, there was a trend toward an association of the TG or
GG genotypes with lepromatous leprosy (OR [odds ratio] 4.76,
95% CI [95% confidence interval] 0.58–38.87, p=0.11) in
comparison to tuberculoid leprosy that did not reach significance.
We also genotyped five additional TLR1 SNPs that are contained
in common TLR1 haplotypes. We did not find associations of any
of these SNPs with leprosy type (Table 2). Analysis of TLR1
haplotypes generated from these six SNPs similarly yielded no
association with leprosy type (data not shown).
TLR1 variant 1805G is associated with protection from
reversal reaction
We next investigated whether T1805G (I602S) might be
associated with ENL or RR, a Th1-mediated immune event
clinically manifested by inflamed skin lesions, fever, and neuritis.
There was no association of T1805G or any other TLR1
Figure 2. IL-6 production by human primary cells following stimulation with M. leprae. Peripheral blood mononuclear cells were
stimulated for 18 hours and supernatants were assayed for cytokine production by ELISA. PBMCs were derived from whole blood taken from 15
individuals with the genotype 1805TTor 1805TG (TT/TG: dark circles) and 13 individuals with the 1805GG genotypes (GG: open circles). (A): PBMCs
stimulated in triplicate with media, PAM2 at 75 ng/ml (P2 75), PAM3 at 75 ng/ml (P3 75), or LPS at 10 ng/ml (LPS 10). (B): PBMCs stimulated in
triplicate with whole irradiated ML at 20 or 100 mg/ml (ML20 or ML100) or MLcw at 2 or 10 mg/ml (MLcw 2 or MLcw10). The mean level and standard
error of the mean are depicted and were derived from averaging the responses of individuals stimulated in triplicate. The median level is depicted by
a bar. *P#0.01, **P#0.001 by Mann–Whitney U-test.
doi:10.1371/journal.pntd.0000231.g002
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associated with a reduced risk of developing RR in comparison to
the 1805T allele (Table 3). The allele frequency of 1805G was
3.9% in those with RR versus 7.4% in those without (unadjusted
OR 0.51, 95% CI 0.29–0.87, p=0.01). The distribution of the
genotype frequencies was also significantly different with a p value
of 0.05 (Table 3). We next examined whether this association was
affected by population admixture. This cohort contains represen-
tatives of more than 8 different ethnic groups with the majority
belonging to one of four groups (Brahmin, Chhetri, Tamang, and
Newar). There were no significant differences in frequencies of
leprosy type or immunologic reactions among the different ethnic
groups (Table 1). We performed a multivariate logistic regression,
adjusting for ethnicity, and found that the odds ratio remained
significant (OR 0.52, 95% CI 0.30–0.92, p=0.03). We also
adjusted for ethnicity, sex and age as a continuous variable, and
again found that the odds ratio remained significant (OR 0.54,
95% CI, 0.30–0.96, p=0.04).
Previously, we found that TG individuals are intermediate
between TT and GG individuals in responses to TLR1 stimulation
[38]. We therefore investigated the influence of TG heterozygotes
with a recessive (assumes T is recessive to G and compares TT
versus TG/GG frequencies) or a dominant model (assumes T is
dominant over G and compares TT/TG versus GG frequencies).
In the recessive model, we found that the 1805 TG/GG genotypes
were associated with a lower likelihood of RR compared to the TT
genotype (OR 0.55, 95% CI 0.31–0.97, p=0.04). In the dominant
model, the GG genotype was associated with a non-significant
reduction in risk when compared to the TT/TG genotypes (OR
0.15, 95%CI 0.01–2.62, p=0.12).
We next examined other TLR1 polymorphisms to determine
whether there were any additional associations between individual
SNPs or haplotypes and RR. SNP rs5743592, located in intron 2
adjacent to the 59 UTR of TLR1, was found to be associated with
a modestly increased risk of RR (Table 3, OR for allelic
comparison: 1.29, 95% CI 1.02–1.64, p=0.04). When haplotypes
of 6 TLR1 SNPs were examined (Table 4), one haplotype,
TATTAG, was associated with protection from RR (OR 0.55,
95% CI 0.31–0.97, p=0.05). None of the other five haplotypes
had any association with RR. Haplotype TATTAG was the only
haplotype occurring with a frequency greater than 1% that
contained the 1805G allele. Lastly, we examined whether
haplotypes formed from SNPs rs5743592 and 1805 were
associated with altered risk of RR. The haplotype associations
were consistent with the individual effect of each SNP on the risk
RR (Table 4), without any additive or synergistic effects. Together,
these genetic data demonstrate that TLR1 SNP 1805G is
associated with protection from RR.
Discussion
In this manuscript, we demonstrate that a human TLR1 SNP
regulates the innate immune response to ML and is associated
with protection from RR. This is the first study to describe an
association of a TLR1 SNP with a Th1-mediated adaptive
immune response. One weakness of our study is the low frequency
of the 1805G variant in Nepal, which limited our power to detect
associations with leprosy type. However, the relevance of the
1805G SNP to leprosy pathogenesis is supported by work from
Johnson and colleagues, who recently reported an association of
this variant with protection from leprosy in a Turkish cohort [39].
Although these authors do not mention whether or not T1805G
was associated with different forms of leprosy in Turkey or with
immune reactions, this may be due to the small size of their patient
cohort (57 individuals). Genetic association studies that utilize
cohorts of multiple ethnicities are also open to the criticism that
associations are due to the effects of population admixture rather
than the variant of interest. However, when we adjusted for ethnic
composition of the comparision groups, we still found that the
1805G variant was associated with significant protection against
RR.
There are several possible mechanisms by which TLR1 might
affect the pathogenesis of RR. At the cellular level, TLR1 might
exert its influence through control of innate immune functions,
such as the capacity of dendritic cells (DCs) and macrophages to
control bacillary replication. Alternatively, or in addition, SNP
1805 may regulate DC maturation and/or antigen presentation
and thereby influence the activation and maintenance of T cell
responses to M. leprae antigens. Interestingly, recent work by other
investigators demonstrates that the differentiation of monocytes
Figure 3. IL-b and TNF-a production in human mononuclear
cells following stimulation with M. leprae. Peripheral blood
mononuclear cells were stimulated for 18 hours and supernatants
were assayed for cytokine production by luminex multiplex bead assay.
PBMCs were obtained from 11 individuals with the genotype 1805TT or
1805TG (TT/TG: dark circles) and 10 individuals with the 1805GG
genotypes (GG: open circles). PBMCs stimulated with media, PAM2 at
75 ng/mL (P2), PAM3 at 75 ng/mL (P3), or LPS at 10 ng/ml (LPS), whole
irradiated ML at 20 mg/ml (ML) or MLcw at 10 mg/ml (MLcw). IL-1b
production following stimulation is shown in (A), and TNF-a production
in (B). The mean level and standard error of the mean are depicted and
were derived from averaging the responses of individual within each
genotype group. The median level is depicted by a bar; *p#0.05,
**p#0.001 by Mann–Whitney U-test.
doi:10.1371/journal.pntd.0000231.g003
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Characteristics, n (%) All leprosy
1 Brahmin
2 Chhetri Tamang Newar P
3
933 (100.0) 239 (25.6) 208 (22.3) 134 (14.3) 68 (7.3)
Gender
female 280 (30.0) 73 (30.5) 61 (29.3) 44 (32.8) 22 (32.4) 0.92
male 649 (69.6) 166 (69.5) 146 (70.2) 90 (67.2) 46 (67.6)
Age (mean+/2SD) 44.2616.4 45.5615.4 43.6616.7 44.1616.7 51.4617.1
Leprosy type
2
Lepromatous (LL, BL) 551 (59.1) 126 (52.7) 122 (58.7) 89 (66.4) 38 (55.9) 0.26
Borderline (BB) 30 (3.2) 11 (4.6) 5 (2.4) 6 (4.5) 2 (2.9)
Tuberculoid (TT, BT) 343 (36.8) 96 (40.2) 80(38.5) 39 (29.1) 27 (39.7)
Immune Reactions
No RR 695 (74.5) 185 (77.4) 149 (71.6) 89 (66.4) 54 (79.4) 0.07
RR 238 (25.5) 54 (22.6) 59 (28.4) 45 (33.6) 14 (20.6)
No ENL 442 (80.4) 104 (83.2) 106 (86.9) 73 (82.0) 34 (89.5) 0.61
ENL 108 (19.6) 21 (16.8) 16 (13.1) 16 (18.0) 4 (10.5)
1Percentages of individuals in some categories do not sum to 100 due to missing data. Not shown among all leprosy are 8 subjects with peripheral neuropathy (PN), and
one with leprosy of indeterminate type (IN).
2The four most frequent ethnic groups (from . 8 ethnic groups) are tabulated.
3P represents exact P values for overall distribution of gender and age groups within the different ethnic groups and for the overall distribution of leprosy type and
immune reactions among the 4 different ethnic groups.
doi:10.1371/journal.pntd.0000231.t001
Table 2. TLR1 Polymorphism Frequency in Different Leprosy Types.
SNP Allele Frequency (%) OR (95% CI) P
1 Genotype frequency (%)
A
3 aA A A a a a P
2
Trs5743563C
Tuberculoid
4 510 (78.0) 144 (22.0) 196 (59.9) 118 (36.1) 13 (4.0)
Lepromatous 825 (75.1) 273 (24.9) 1.17 (0.93–1.46) 0.18 306 (55.7) 213 (38.8) 30 (5.5) 0.38
Ars5743565G
Tuberculoid 505 (77.7) 145 (22.3) 194 (59.7) 117 (36.0) 14 (4.3)
Lepromatous 829 (75.2) 273 (24.8) 1.15 (0.91–1.44) 0.24 308 (55.9) 213 (38.7) 30 (5.4) 0.49
Trs5743592C
Tuberculoid 493 (75.6) 159 (24.4) 186 (57.1) 121 (37.1) 19 (5.8)
Lepromatous 791 (72.8) 295 (27.2) 1.16 (0.93–1.45) 0.20 286 (52.7) 219 (40.3) 38 (7.0) 0.43
Trs5743595C
Tuberculoid 508 (77.9) 144 (22.1) 195 (59.8) 118 (36.2) 13 (4.0)
Lepromatous 833 (75.6) 269 (24.4) 1.14 (0.91–1.44) 0.27 310 (56.3) 213 (38.7) 28 (5.1) 0.52
G743A
Tuberculoid 359 (55.6) 287 (44.4) 107 (33.1) 145 (44.9) 71 (22.0)
Lepromatous 604 (55.7) 480(44.3) 0.99 (0.82–1.21) 0.95 172 (31.7) 260 (48.0) 110 (20.3) 0.67
T1805G
Tuberculoid 586 (94.2) 36 (5.8) 276 (88.7) 34 (10.9) 1 (0.3)
Lepromatous 912 (93.1) 68 (6.9) 1.21 (0.80–1.84) 0.36 430 (87.8) 52 (10.6) 8 (1.6) 0.23
1P value for comparison of allele frequencies.
2P value for comparison of genotype frequencies.
3A denotes common allele, a denotes minor allele.
4Tuberculoid includes TT and BT. Lepromatous includes LL, BL, and BB.
doi:10.1371/journal.pntd.0000231.t002
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signaling [35,36]. For example, the 19 kDa protein of MTb signals
through TLR2/1 to downregulate MHC class I and II antigen
presentation by macrophages, leading to impaired T cell
activation [45]. We have previously shown that ML also exerts
an inhibitory effect on APC activation and maturation, through an
as-yet unidentified mechanism [46]. In LL patients who are
clinically stable, macrophages within LL lesions contain numerous
bacilli that are seemingly resistant to host killing [47,48]. However,
this inhibition of phagocyte function seems to be overturned
during RR. When patients undergo RR, the bacilli within these
macrophages are rapidly cleared. This clearance coincides with
the influx into the lesion of CD1b+ DC, which activate M. leprae-
specific T cells and thereby promote intracellular killing.
Importantly, the generation of CD1b+ DCs appears to be
dependent on signaling through TLR2/1 [48]. Here, we show
that individuals carrying the 1805G SNP are protected against
reversal reactions. Our data suggests that TLR1 may be an
important regulator of these effects on DCs.
At the molecular level, the defect in 1805G signaling is likely
due to a failure to express or retain TLR1 on the cell surface.
Johnson recently showed that monocytes from 1805GG individ-
uals completely lack surface TLR1, although total levels of this
receptor are normal [39]. In Nepal, we observed a trend toward
an association of the 1805G variant with lepromatous rather than
tuberculoid leprosy. This trend, although not statistically signifi-
cant, is consistent with impaired Th1 immunity, which is required
for the tuberculoid form of the disease. An association of 1805G
with lepromatous leprosy could explain the intriguing earlier
observation by Krutzik and coworkers, who examined TT and LL
lesions and were unable to detect any TLR1 staining in LL lesions
[29]. Collectively, these findings suggest that TLR1 biology is
different in lepromatous leprosy than in other forms of the disease.
The absence of membrane-inserted TLR1 in 1805GG individuals
may be associated with a Th2 immune response that arises by
Table 3. TLR1 Polymorphism Frequency in Reversal Reaction.
SNP Allele Frequency (%) OR (95% CI) P
1 Genotype frequency (%) P
2
A
3 aA A A a a a
Trs5743563C
No reaction 1014 (77.3) 298 (22.7) 1.00 388 (59.1) 238 (36.3) 30 (4.6)
Reaction 335 (73.5) 121 (26.5) 1.23 (0.96–1.57) 0.10 120 (52.6) 95 (41.7) 13 (5.7) 0.22
Ars5743565G
No reaction 1013 (77.1) 301 (22.9) 1.00 388 (59.1) 237 (36.1) 32 (4.9)
Reaction 335 (73.8) 119 (26.2) 1.20 (0.94–1.53) 0.15 120 (52.9) 95 (41.9) 12 (5.3) 0.26
Trs5743592C
No reaction 984 (75.2) 324 (24.8) 1.00 371 (56.7) 242 (37.0) 41 (6.3)
Reaction 313 (70.2) 133 (29.8) 1.29 (1.02–1.64) 0.04 106 (47.5) 101 (45.3) 16 (7.2) 0.06
Trs5743595C
No reaction 1017 (77.4) 297 (22.6) 1.00 389 (59.2) 239 (36.4) 29 (4.4)
Reaction 338 (74.1) 118 (25.9) 1.20 (0.94–1.53) 0.16 122 (53.5) 94 (41.2) 12 (5.3) 0.32
G743A
No reaction 710 (54.7) 588 (45.3) 1.00 202 (31.1) 306 (47.1) 141 (21.7)
Reaction 262 (58.5) 186 (41.5) 0.86 (0.69–1.07) 0.17 80 (35.7) 102 (45.5) 42 (18.8) 0.39
T1805G
No reaction 1117 (92.6) 89 (7.4) 1.00 523 (86.7) 71 (11.8) 9 (1.5)
Reaction 396 (96.1) 16 (3.9) 0.51 (0.29–0.87) 0.01 190 (92.2) 16 (7.8) 0 (0.0) 0.05
4
1P value for comparison of allele frequencies by Chi-square.
2P value for comparison of genotype frequencies calculated by Chi-square unless otherwise indicated.
3A denotes common allele, a denotes minor allele.
4P value calculated by Fisher’s Exact test due to small cell number.
doi:10.1371/journal.pntd.0000231.t003
Table 4. Frequency of TLR1 haplotypes in reversal reaction.
6 SNP
Haplotypes
1 Reversal Reaction OR (95% CI) P
3
No Yes
TATTAT 441 (37.8) 155 (38.1) 1.00
TATTGT 356 (30.5) 116 (28.5) 0.93 (0.70–1.22) 0.68
CGCCGT 259 (22.2) 105 (25.8) 1.15 (0.86–1.54) 0.46
TATTAG 82 (7.1) 16 (3.9) 0.55 (0.31–0.97) 0.05
TACTGT 26 (2.2) 15 (3.7) 1.64 (0.85–3.17) 0.15
CGCCGG 2 (0.1) 0 (0.0) 0.25 (0.00–51.20) 0.58
2 SNP Haplotypes
2
TT 808 (68.0) 272 (66.4) 1.00
CT 294 (24.7) 122 (29.7) 1.23 (0.95–1.58) 0.18
TG 83 (7.0) 16 (3.8) 0.56 (0.32–0.97) 0.05
CG 3 (0.3) 0 (0.1) 0.41 (0.02–10.61) 0.58
1Order for 6 SNP haplotypes, left to right: Trs5743563C, Ars5743565G,
Trs5743592C, Trs5743595C, G743A, T1805G.
2Order for 2 SNP haplotypes: Trs5743592C, T1805G.
3P value represents comparison of a given haplotype with the reference
haplotype TATTAT.
doi:10.1371/journal.pntd.0000231.t004
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bias may in turn permit continued replication of the M. leprae
bacillus and result in the clinical phenotype of LL.
In our initial characterization of TLR1_T1805G, we found that
this polymorphism is present in up to 76% of Caucasian
Americans and is associated with a defect in innate responses to
bacterial lipopeptide [38]. Worldwide, the T1805G polymorphism
has variable frequency across ethnic groups. In Turkey, the allele
frequency of this variant is 43% [39], while among African
Americans and Vietnamese individuals, it has a frequency of 25%
and 1%, respectively [38]. A broad array of pathogens are sensed
by TLR2, and consequently by TLR2/1 or TLR2/6 heterodi-
mers. These microorganisms include gram-positive and gram-
negative bacteria, fungi, parasites, and mycobacteria [49]. Given
the association of TLR1 1805G with Th1-mediated immune
events, this SNP may influence the pathogenesis of any number of
inflammatory conditions, including chronic mycobacterial infec-
tion, autoimmune disorders, sepsis and allergic reactions.
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